Moreover, the in vitro sensitivity of the Nf1-ko endothelial cell proliferation and the normalization of the vascular morphogenesis following treatment with low-dose rapamycin suggests that anti-tumor drugs may be effective for treating certain types of vascular dysfunctions in NF1 patients [43,44]. The gene discussed is NF1; the disease is neoplasm.